Business Context and Reporting Period
This Form 8-K Current Report was filed by iBio, Inc. on October 19, 2020. The filing addresses corporate governance changes, specifically the departure of a director and the reclassification of another director to maintain board balance.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel and board composition changes rather than financial performance.
Material Changes
- Director Resignation: Philip K. Russell, M.D., resigned from the Board of Directors and the Science and Technology Committee effective immediately due to personal health reasons. The resignation was not related to any disagreement with the Company.
- Director Reclassification: To rebalance the three classes of directors, Alexandra K. Kropotova, M.D., resigned from her position as a Class III director and was immediately reappointed as a Class II director. Her service is deemed uninterrupted.
- Board Size Reduction: Following the reappointment, the Board decreased the number of authorized directors from ten to nine.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding future operations. No specific risks or contingencies were disclosed in this report other than the personal health reasons cited for Dr. Russell's departure.
Key Facts for Investor Verification
- Verify the current composition of the Board of Directors and the Science and Technology Committee following the changes.
- Confirm the updated number of authorized directors (nine) in the Company's charter or bylaws.
- Check for any subsequent filings regarding the appointment of a new director to replace Dr. Russell, if applicable.